肿瘤氨基酸代谢重编程的靶向治疗研究进展

Research Progress of Targeted Therapy of Amino Acid Metabolic Reprogramming in Tumors

摘要

氨基酸代谢重编程是肿瘤的主要生物学特征之一，可参与调控肿瘤表观遗传修饰与多条细胞信号转导通路。同时，越来越多的证据表明，肿瘤细胞借助该重编程实现免疫逃逸，并由此诱导肿瘤细胞产生治疗耐受表型。因此，靶向氨基酸代谢通路已成为肿瘤治疗的可行策略之一。系统梳理肿瘤细胞及其肿瘤微环境内免疫细胞的氨基酸代谢重编程特征，阐明氨基酸代谢与多条信号通路之间的相互作用，归纳相关潜在药物靶点及药物研发现状；同时展望氨基酸代谢重编程用于肿瘤治疗的潜在研究方向，为靶向氨基酸代谢的肿瘤治疗提供参考。

Abstract

As one of the major biological hallmarks of tumors, amino acid metabolic reprogramming participates in the regulation of tumor epigenetic modifications and multiple cellular signal transduction pathways. Meanwhile, numerous evidence indicates that tumor cells achieve immune escape via such reprogramming, which in turn induces tumor cells to develop a treatment-tolerant phenotype. Consequently, targeting amino acid metabolic pathways has become one of the feasible strategies for tumor therapy. This paper systematically summarizes the features of amino acid metabolic reprogramming in tumor cells and immune cells within the tumor microenvironment, elucidates the interactions between amino acid metabolism and multiple signaling pathways, and summarizes relevant potential drug targets and the research and development status of corresponding agents, with a prospect of the research directions of amino acid metabolic reprogramming in tumor therapy, so as to provide some reference for tumor therapy targeting amino acid metabolism.

关键词

氨基酸代谢 / 促癌信号 / 肿瘤微环境 / 靶向药物 / 肿瘤治疗

Key words

amino acid metabolism / cancer-promoting signal / tumor microenvironment / targeted drug / cancer treatment

参考文献

[1] Yang K, Wang X, Song C,et al. The role of lipid metabolic reprogramming in tumor microenvironment[J].Theranostics, 2023, 13(6):1774-1808.

[2] Chen J, Cui L, Lu S,et al. Amino acid metabolism in tumor biology and therapy[J].Cell Death Dis, 2024, 15(1):42.

[3] Rubin A L . Suppression of transformation by and growth adaptation to low concentrations of glutamine in NIH—3T3 cells[J].Cancer Res, 1990, 50(9):2832-2839.

[4] Rabinovich S, Adler L, Yizhak K,et al. Diversion of aspartate in ASS1—deficient tumours fosters de novo pyrimidine synthesis[J].Nature, 2015, 527(7578):379-383.

[5] Mossmann D, Müller C, Park S,et al. Arginine reprograms metabolism in liver cancer via RBM39[J].Cell, 2023, 186(23):5068-5083.e23.

[6] Yang K, Xu C, Sun H,et al. Branched—chain keto—acid dehydrogenase kinase regulates vascular permeability and angiogenesis to facilitate tumor metastasis in renal cell carcinoma[J].Cancer Sci, 2023, 114(11):4270-4285.

[7] Xue C, Li G, Zheng Q,et al. Tryptophan metabolism in health and disease[J].Cell Metab, 2023, 35(8):1304-1326.

[8] 赵祎, 王萌, 杨洋. 肿瘤中甲硫氨酸代谢及其相关基因的表达调控[J].中国生物化学与分子生物学报, 2022, 38(7):849-857.

[9] Bian Y, Li W, Kremer D M,et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation[J].Nature, 2020, 585(7824):277-282.

[10] Pascale R M, Simile M M, Calvisi D F,et al. S—adenosylmethionine: from the discovery of its inhibition of tumorigenesis to its use as a therapeutic agent[J].Cells, 2022, 11(3):409.

[11] Chen J, Ou Y, Luo R,et al. SAR1B senses leucine levels to regulate mTORC1 signalling[J].Nature, 2021, 596(7871):281-284.

[12] Wolfson R L, Chantranupong L, Saxton R A,et al. Sestrin2 is a leucine sensor for the mTORC1 pathway[J].Science, 2016, 351(6268):43-48.

[13] Chantranupong L, Scaria S M, Saxton R A,et al. The CASTOR proteins are arginine sensors for the mTORC1 pathway[J].Cell, 2016, 165(1):153-164.

[14] Gu X, Orozco J M, Saxton R A,et al. SAMTOR is an S—adenosylmethionine sensor for the mTORC1 pathway[J].Science, 2017, 358(6364):813-818.

[15] Bodineau C, Tomé M, Murdoch P D S,et al. Glutamine, MTOR and autophagy: a multiconnection relationship[J].Autophagy, 2022, 18(11):2749-2750.

[16] Son J, Lyssiotis C A, Ying H,et al. Glutamine supports pancreatic cancer growth through a KRAS—regulated metabolic pathway[J].Nature, 2013, 496(7443):101-105.

[17] Najumudeen A K, Ceteci F, Fey S K,et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS—mutant colorectal cancer[J].Nat Genet, 2021, 53(1):16-26.

[18] Liu Y, Su Z, Tavana O,et al. Understanding the complexity of p53 in a new era of tumor suppression[J].Cancer Cell, 2024, 42(6):946-967.

[19] Yoo Y A, Quan S, Yang W,et al. Asparagine dependency is a targetable metabolic vulnerability in TP53—altered castration—resistant prostate cancer[J].Cancer Res, 2024, 84(18):3004-3022.

[20] Tombari C, Zannini A, Bertolio R,et al. Mutant p53 sustains serine—glycine synthesis and essential amino acids intake promoting breast cancer growth[J].Nat Commun, 2023, 14(1):6777.

[21] Koo K Y, Moon K, Song H S,et al. Metabolic regulation by p53: implications for cancer therapy[J].Mol Cells, 2025, 48(4):100198.

[22] Liu Y, Mao C, Wang M,et al. Cancer progression is mediated by proline catabolism in non—small cell lung cancer[J].Oncogene, 2020, 39(11):2358-2376.

[23] Nunes E A, Lomax A R, Noakes P S,et al. β—Hydroxy—β—methylbutyrate modifies human peripheral blood mononuclear cell proliferation and cytokine production in vitro [J].Nutrition, 2011, 27(1):92-99.

[24] Fu J, Han Z, Wu Z,et al. GABA regulates IL—1β production in macrophages[J].Cell Rep, 2022, 41(10):111770.

[25] Zhu Y, Zhou Z, Du X,et al. Cancer cell—derived arginine fuels polyamine biosynthesis in tumor—associated macrophages to promote immune evasion[J].Cancer Cell, 2025, 43(6):1045-1060.e7.

[26] Wilson J L, Nägele T, Linke M,et al. Inverse data—driven modeling and multiomics analysis reveals phgdh as a metabolic checkpoint of macrophage polarization and proliferation[J].Cell Rep, 2020, 30(5):1542-1552.e7.

[27] Wang F, Liu L, Wang J,et al. Gain—of—function of IDO in DCs inhibits T cell immunity by metabolically regulating surface molecules and cytokines[J].Exp Ther Med, 2023, 25(5):234.

[28] Yang L, Chu Z, Liu M,et al. Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy[J].J Hematol Oncol, 2023, 16(1):59.

[29] Lasser S A, Ozbay Kurt F G, Arkhypov I,et al. Myeloid—derived suppressor cells in cancer and cancer therapy[J].Nat Rev Clin Oncol, 2024, 21(2):147-164.

[30] Abd El—Fattah E E . IDO/kynurenine pathway in cancer: possible therapeutic approaches[J].J Transl Med, 2022, 20(1):347.

[31] Platten M, Wick W, van den Eynde B J . Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion[J].Cancer Res, 2012, 72(21):5435-5440.

[32] Chen Y, Tan L, Gao J,et al. Targeting glutaminase 1 (GLS1) by small molecules for anticancer therapeutics[J].Eur J Med Chem, 2023, 252:115306.

[33] Wicker C A, Hunt B G, Krishnan S,et al. Glutaminase inhibition with telaglenastat (CB—839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models[J].Cancer Lett, 2021, 502:180-188.

[34] Monsen P J, Bommi P V, Grigorescu A A,et al. Rational design and optimization of a potent IDO1 proteolysis targeting Chimera (PROTAC) [J].J Med Chem, 2025, 68(4):4961-4987.

[35] Menjivar R E, Nwosu Z C, Du W,et al. Arginase 1 is a key driver of immune suppression in pancreatic cancer[J].eLife, 2023, 12:e80721.

[36] Ji J X, Cochrane D R, Tessier—Cloutier B,et al. Arginine depletion therapy with ADI—PEG20 limits tumor growth in argininosuccinate synthase—deficient ovarian cancer, including small—cell carcinoma of the ovary, hypercalcemic type[J].Clin Cancer Res, 2020, 26(16):4402-4413.

[37] Peng H, Yan Y, He M,et al. SLC43A2 and NFκB signaling pathway regulate methionine/cystine restriction—induced ferroptosis in esophageal squamous cell carcinoma via a feedback loop[J].Cell Death Dis, 2023, 14(6):347.

[38] Chang Y, Wang N, Li S,et al. SLC3A2—mediated lysine uptake by cancer cells restricts T—cell activity in hepatocellular carcinoma[J].Cancer Res, 2025, 85(12):2250-2267.

[39] Lemberg K M, Vornov J J, Rais R,et al. We 're not ''DON '' yet: optimal dosing and prodrug delivery of 6—diazo—5—oxo—L—norleucine [J].Mol Cancer Ther, 2018, 17(9):1824-1832.

[40] Praharaj M, Shen F, Lee A J,et al. Metabolic reprogramming of tumor—associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid—rich prostate and bladder cancers[J].Cancer Immunol Res, 2024, 12(7):854-875.

[41] Ouyang Y, Ou Z, Zhong W,et al. FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune—inert macrophages that suppress T—cell recruitment and activation[J].Cancer Res, 2023, 83(24):4030-4046.

[42] Yokoyama Y, Estok T M, Wild R . Sirpiglenastat (DRP—104) induces antitumor efficacy through direct, broad antagonism of glutamine metabolism and stimulation of the innate and adaptive immune systems[J].Mol Cancer Ther, 2022, 21(10):1561-1572.

[43] Zheng X, Liu Y, Liu Y,et al. Arginine—assembly as NO nano—donor prevents the negative feedback of macrophage repolarization by mitochondrial dysfunction for cancer immunotherapy[J].Biomaterials, 2024, 306:122474.

[44] Lee C H, Motzer R, Emamekhoo H,et al. Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double—blinded, placebo—controlled, phase II ENTRATA trial[J].Clin Cancer Res, 2022, 28(15):3248-3255.

[45] Steggerda S M, Bennett M K, Chen J,et al.Inhibition of arginase by CB—1158 blocks myeloid cell—mediated immune suppression in the tumor microenvironment[J].J Immunother Cancer, 2017, 5(1):101.

[46] Sosnowska A, Chlebowska—Tuz J, Matryba P,et al. Inhibition of arginase modulates T—cell response in the tumor microenvironment of lung carcinoma[J].Oncoimmunology, 2021, 10(1):1956143.

[47] Pavlova N N, Hui S, Ghergurovich J M,et al. as extracellular glutamine levels decline, asparagine becomes an essential amino acid[J].Cell Metab, 2018, 27(2):428-438.e5.

[48] Garcia—Bermudez J, Badgley M A, Prasad S,et al. Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia[J].Nat Metab, 2022, 4(6):724-738.

[49] Shen Y, Wang H, Guo D,et al. Dual asparagine—depriving nanoparticles against solid tumors[J].Nat Commun, 2025, 16(1):5675.

[50] Do L K, Lee H M, Ha Y S,et al. Amino acids in cancer: understanding metabolic plasticity and divergence for better therapeutic approaches[J].Cell Rep, 2025, 44(4):115529.

基金资助

国家自然科学基金资助项目(82372973)